Guidance
Evidence-based recommendations on the Senza spinal cord stimulation system for delivering HF10 therapy to treat chronic neuropathic pain.
Implementation
NICE has developed tools, in association with relevant stakeholders, to help organisations put this guidance into practice.
Is this guidance up to date?
August 2023: We reviewed the guidance and found nothing new that affects the recommendations in this guidance (see the review decision).
Next review: This guidance will be reviewed if there is new evidence that is likely to change the recommendations.
Guidance development process
How we develop NICE medical technologies guidance
NICE medical technologies guidance addresses specific technologies notified to NICE by sponsors. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice. If the case for adopting the technology is supported, then the technology has been found to offer advantages to patients and the NHS. The specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.